Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 01, 2021

SELL
$4.0 - $9.2 $11.7 Million - $26.9 Million
-2,922,819 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$7.66 - $10.78 $7.71 Million - $10.8 Million
1,006,439 Added 52.52%
2,922,819 $23.3 Million
Q2 2020

Aug 07, 2020

BUY
$2.58 - $12.1 $4.94 Million - $23.2 Million
1,916,380 New
1,916,380 $19.2 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $121M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.